Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Dec;60(6):934–937. doi: 10.1038/bjc.1989.393

Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy.

R T Oliver 1, D Crosby 1, A Nouri 1, E Scott 1, A Galazka 1
PMCID: PMC2247261  PMID: 2605101

Abstract

Seventeen patients with terminal malignancy have been entered into a sequential investigation of two doses of continuous infusion recombinant interleukin-2 (bioleukin) given in the setting of a general ward. After an initial experience of a dose of 300 micrograms m-2 in eight patients the remainder received 400 micrograms m-2. Temporary interruption of treatment at the first sign of any serious toxicity led to rapid resolution of side-effects. No patient needed intensive care support, although nine of 17 required temporary interruption of infusion, lasting on average 4 h. Median lymphocyte rebound on day 14 was 3.6 times the pre-treatment level. It remained above pre-treatment levels in four of five patients who had no shown disease progression at day 56 after more than 28 days off treatment. Minor responses occurred in five patients, lasting on average 4 months.

Full text

PDF
934

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cheever M. A., Thompson J. A., Kern D. E., Greenberg P. D. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. J Immunol. 1985 Jun;134(6):3895–3900. [PubMed] [Google Scholar]
  2. Gambacorti-Passerini C., Radrizzani M., Marolda R., Belli F., Sciorelli G., Galazka A. R., Schindler J. D., Cascinelli N., Parmiani G. In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2. Int J Cancer. 1988 May 15;41(5):700–706. doi: 10.1002/ijc.2910410511. [DOI] [PubMed] [Google Scholar]
  3. Kern P., Toy J., Dietrich M. Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut. 1985 Jan;50(1):1–6. doi: 10.1007/BF00319762. [DOI] [PubMed] [Google Scholar]
  4. Kirkwood J. M., Ernstoff M. S. Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr;2(4):336–352. doi: 10.1200/JCO.1984.2.4.336. [DOI] [PubMed] [Google Scholar]
  5. Kohler P. C., Hank J. A., Moore K. H., Storer B., Bechhofer R., Sondel P. M. Phase 1 clinical evaluation of recombinant interleukin-2. Prog Clin Biol Res. 1987;244:161–172. [PubMed] [Google Scholar]
  6. Lotze M. T., Matory Y. L., Ettinghausen S. E., Rayner A. A., Sharrow S. O., Seipp C. A., Custer M. C., Rosenberg S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985 Oct;135(4):2865–2875. [PubMed] [Google Scholar]
  7. Marolda R., Belli F., Prada A., Villani F., Gambacorti-Passerini C., Galazka A., Parmiani G., Cascinelli N. A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects. Tumori. 1987 Dec 31;73(6):575–584. doi: 10.1177/030089168707300606. [DOI] [PubMed] [Google Scholar]
  8. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  9. Thompson J. A., Lee D. J., Lindgren C. G., Benz L. A., Collins C., Levitt D., Fefer A. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol. 1988 Apr;6(4):669–678. doi: 10.1200/JCO.1988.6.4.669. [DOI] [PubMed] [Google Scholar]
  10. Vetto J. T., Papa M. Z., Lotze M. T., Chang A. E., Rosenberg S. A. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol. 1987 Mar;5(3):496–503. doi: 10.1200/JCO.1987.5.3.496. [DOI] [PubMed] [Google Scholar]
  11. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES